Danaher Corp. said it will acquire Abcam Plc in a deal worth $5.7 billion, beating out rivals in a race to acquire the UK-based maker of supplies for the life-sciences industry whose technologies are used by thousands of researchers.
Danaher will pay $24 a share for Cambridge, England based Abcam, according to a statement Monday. The transaction, which includes debt and acquired cash, is seen closing in mid-2024, and Danaher expects to fund it using cash and proceeds from issuing commercial paper.
Sometimes called the “Amazon of antibodies,” Abcam provides scientists with a variety of laboratory products including the immune proteins used in drug discovery and diagnostics. The acquisition will help Danaher, a maker of laboratory equipment and other supplies, in its efforts to provide full services for customers.
Read the full story on Bloomberg here.